-
Beam Therapeutics' (BEAM) "Overweight" Rating Reaffirmed at Cantor Fitzgerald
Source: Buzz FX / 13 Mar 2025 11:46:17 America/New_York
Beam Therapeutics' (BEAM) "Overweight" Rating Reaffirmed at Cantor Fitzgerald Written by MarketBeat March 13, 2025 Share Link copied to clipboard. Remove Ads Beam Therapeutics ( NASDAQ:BEAM - Get Free Report ) 's stock had its "overweight"
Read more...